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latency between putative infection or insult and the emer-
gence of psychotic symptoms complicates establishing
direct links. While most reports have been ecologic studies
without confirmed maternal infection, Brown et al. (10)
found that 20.4% of persons with a documented in utero
exposure to rubella developed an adult schizophrenia spec-
trum disorder. Experimentally, lymphocytic choriomenin-
gitis virus infection in a neonatal rat model produces some
latent changes similar to those of schizophrenia, e.g., hip-
pocampal atrophy and impaired inhibitory GABA neuro-
transmission (11); blocking IL-1 partially attenuates the
hippocampal cell loss. Inflammatory cytokine responses,
perhaps amplified by immunogenetic abnormalities, may
be a common thread linking intrapartum infections and
noninfectious gestational and obstetric complications to
neurodevelopmental disorders (12).
Keys to the Future
A continuum from acute infection to chronic disease
exists, and each stage is an opportunity to prevent or min-
imize an avoidable fraction of chronic disease– that result-
ing from infectious disease. Crucial steps include
identifying infectious etiologies and cofactors, determin-
ing persons (including women) at risk for infection or out-
come, and implementing measures that minimize chronic
sequelae. Research incorporating longitudinal studies that
precede clinical disease must support evidenced-based
conclusions and actions. The benefits to women could be
substantial.
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Disproportionate Impact of
Sexually Transmitted
Diseases on Women
Worldwide, sexually transmitted diseases (STDs) and
HIV affect women more than men. This gender differential
is greater in developing countries than in industrialized
countries, and biological, social, cultural, and economic
factors all contribute to the gender differential in STD/HIV.
Larger mucosal surface area, microlesions caused during
sex (particularly forced sex), and the presence of more HIV
in semen than in vaginal secretions all contribute to
women's greater vulnerability to STDs and HIV.
Their sex partners’ behaviors also put women at risk for
STDs and HIV. Culturally, men are expected to have mul-
tiple sex partners, including sex workers, and women may
risk abuse or suspicion of infidelity if they refuse sex or
request protection. Financial and material dependence on
men renders women economically more vulnerable to
STDs and HIV. Often women are under pressure to find a
husband or bring home money, which in the absence of
viable alternatives leads them into sex work. Effective pre-
vention of STDs and HIV necessitates large-scale social,
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cultural, and economic changes and female-controlled pre-
vention, such as microbicides.
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Impact of HIV on Women in
the United States
In the United States, AIDS was first reported in women
in 1981 (1), and the percentage of AIDS cases in women
has continued to increase, accounting for an estimated
26% of new AIDS diagnoses in 2002 (2). Since 1998,
deaths among women with AIDS in the United States have
remained stable at an estimated 4,000 (2).
Epidemiologic Features of HIV in 
Women, United States
Data from 29 states with confidential name-based HIV
reporting since 1998 were used to describe the status of
HIV disease among women from 1999 through 2002. HIV
diagnoses were defined as diagnoses of HIV infection
regardless of AIDS diagnosis status. This diagnosis
includes persons with a diagnosis of HIV infection only,
HIV infection and later AIDS diagnosis, or concurrent
diagnoses of HIV infection and AIDS.
From 1999 through 2002, an estimated 101,872 HIV
diagnoses were reported from 29 states: 72,007 (70.7%) in
men and 29,865 (29.3%) in women. Among women,
71.9% were non-Hispanic blacks, 18.2% were non-
Hispanic whites, 8.4% were Hispanics, 0.6% were
American Indian/Alaska Natives, and 0.4% were
Asian/Pacific Islanders. The two principal modes of HIV
exposure for women were heterosexual contact and injec-
tion drug use, accounting for 77.7% and 20.5% of diag-
noses among women, respectively. Women were
diagnosed with HIV at younger ages than men. For the 4-
year period, 31.3% of women with HIV were in the 13- to
29-year age group compared with 19.9% of men in the
same age group. HIV diagnosis rates were consistently
higher among non-Hispanic black women compared with
women from other racial and ethnic groups for all 4 years.
Prevention Strategies for Women
In 2003, the Centers for Disease Control and
Prevention (CDC) introduced the Advancing HIV
Prevention (AHP) initiative (3). AHP aims to reduce barri-
ers to early diagnosis of HIV infection, increase access to
quality medical care and treatment, and provide ongoing
prevention services for persons living with HIV. AHP
incorporates four priority strategies: make voluntary HIV
testing a routine part of medical care, implement new mod-
els for diagnosing HIV infections outside of the medical
settings, prevent new infections by working with persons
diagnosed with HIV and their partners, and decrease peri-
natal transmission.
Clinical Care of Women with HIV
HIV-infected women may be at increased risk for med-
ical problems and metabolic changes. Studies have shown
that HIV-positive women were more likely to develop gen-
ital warts and cervical intraepithelial neoplasia (4) and
were at increased risk for viral infections (5). According to
one study, HIV-positive women were 80% more likely to
be anemic than HIV-positive men (6). Compared with
HIV-negative controls, women with HIV were more likely
to have elevated triglycerides and insulin levels (7) and
decreased bone mineral density (8).
Determining when to initiate antiretroviral therapy for
HIV-infected women is based on CD4+ T cell count (9).
Because no gender difference exists for initiating or apply-
ing antiretroviral drug regimens, the guidelines for treating
women are the same as those for treating men. Overall,
drug efficacy does not differ by gender in randomized clin-
ical trials. 
For many reasons, women with HIV may avoid HIV
testing and care. Often, women may be stigmatized and
endure discrimination because of their HIV status. Women
are often the primary caregivers for other family members,
which may lead to avoiding or delaying testing and care.
Economic dependence on a spouse or significant other
may also play a role in whether a woman seeks testing and
care. Mistrust of the healthcare system may also exist.
Depression or domestic violence may also affect a
woman's ability to seek needed care for HIV infection.
Incorporating HIV Prevention into Medical Care
In 2003, CDC, the Health Resources and Services
Administration, National Institutes of Health, and the HIV
Medicine Association of the Infectious Diseases Society of
America issued recommendations to assist clinicians in
integrating HIV prevention into primary care for HIV-
infected persons. Providers are encouraged to deliver brief
prevention messages during primary care visits, screen for
HIV risk behaviors and sexually transmitted disease, pro-
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